Covid Medicine Delivery Unit
On behalf of:
- Coventry and Warwickshire CCG
- CRW Federation Collaborative
- George Eliot Hospital
- South Warwickshire Foundation Trust
- University Hospitals Coventry and Warwickshire
About the Service
NHS England has directed health service providers to develop CMDUs to deliver COVID treatments to non-hospitalised patients who are at risk of disease progression, deterioration, hospitalisation and death
The treatments include nMABs (neutralizing monoclonal antibodies) infusions and oral antivirals.
The treatments are a key element in the offer to higher risk patients, reducing hospital admissions and death
The model adopted across Rugby, Coventry and Warwickshire ICS consists of an end to end integrated approach, with primary care, acute secondary care hubs supporting local patients, and community follow up
The Federation Collaborative COVID@home service will triage all patients referred via the national web view platform and referrals made by GPs, NHS 111 and CWPT
Patients will be streamed to the right outcome service (infusion, antivirals or community management)
Intravenous infusions of the NMABs, and dispensing of oral anti-virals will occur at all 3 Acutes dependent on where they live
All patients (irrespective of whether or not they are eligible for medication) will be followed up by the virtual ward team as appropriate.
Action required by GP
If your patient is possibly eligible for medication or contacts the practice because they have received a message suggesting they may be eligible for medication, please complete the attached form.
It only requires you to tick a single box and the team will triage, advise and consent the patient as well as organise referral as appropriate to an acute service.
Monitoring will also be organised.
The team will document information in the patient’s EMIS notes.
An EMIS version of the form will be made available
Inclusion criteria for NMABs Infusion:
C-19 symptom onset within 5 days & PCR test positive plus must have any of the following:
- Downs Syndrome/ genetic disorders
- Solid organ cancer
- Haematological malignancy
- Renal disease / solid organ transplant patient
- Liver diseases/Cirrhosis
- Immune medicated inflammatory disorders
- Primary Immunity deficiency
- Sickle cell
- Rare neurological conditions (e.g. MND, MS, Huntingdon’s, MG)
- No history of anaphylaxis or allergy to monoclonal antibodies
- No other interaction with drugs precluding use of monoclonal antibody treatment
- Over 18
- Aged 12-18 – separated local process
- Requires hospitalisation
- New need of oxygen treatment
- Suitability to travel for treatment
- Where NMAB is contra-indicated
Any queries please email us on email@example.com
Click on image for printable version or follow link right